These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38914453)
1. Carbapenemen-resistant Enterobacterales: An issue of global concern. Nastro M Rev Argent Microbiol; 2024; 56(2):113-114. PubMed ID: 38914453 [No Abstract] [Full Text] [Related]
2. Prevalence of Invasive Infections Due to Carbapenem-Resistant Enterobacteriaceae among Adult Patients in U.S. Hospitals. Lodise T; Ye MJ; Zhao Q Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559271 [TBL] [Abstract][Full Text] [Related]
3. Positive rate for carbapenem-resistant Enterobacterales in hospital water environment: a single-centre study in South Korea. Jo JL; Lee JY; Kim JY; Lim YJ; Kim EO; Jung J; Kim SH J Hosp Infect; 2024 Jul; 149():203-205. PubMed ID: 38599496 [No Abstract] [Full Text] [Related]
4. Carbapenem-Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacterales in Children, United States, 2016-2020. Grome HN; Grass JE; Duffy N; Bulens SN; Ansari U; Campbell D; Lutgring JD; Gargis AS; Masters T; Kent AG; McKay SL; Smith G; Wilson LE; Vaeth E; Evenson B; Dumyati G; Tsay R; Phipps E; Flores K; Wilson CD; Czaja CA; Johnston H; Janelle SJ; Lynfield R; O'Malley S; Vagnone PS; Maloney M; Nadle J; Guh AY Emerg Infect Dis; 2024 Jun; 30(6):1104-1114. PubMed ID: 38781979 [TBL] [Abstract][Full Text] [Related]
6. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study. Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae. Neuner EA; Gallagher JC Virulence; 2017 May; 8(4):440-452. PubMed ID: 27589330 [TBL] [Abstract][Full Text] [Related]
8. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. Tompkins K; van Duin D Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2053-2068. PubMed ID: 34169446 [TBL] [Abstract][Full Text] [Related]
9. Successful treatment of invasive carbapenemase-producing Enterobacteriaceae infections in children using carbapenem-aminoglycoside combination therapy: A case series. Williams PCM; Bartlett AW; Palasanthiran P; Armstrong B; McMullan BJ Infect Dis Health; 2020 Nov; 25(4):314-318. PubMed ID: 32698988 [TBL] [Abstract][Full Text] [Related]
10. Carbapenem-Resistant Enterobacteriaceae: An update narrative review from Saudi Arabia. Alotaibi F J Infect Public Health; 2019; 12(4):465-471. PubMed ID: 31060974 [TBL] [Abstract][Full Text] [Related]
11. Phenotypic and molecular characterization of multidrug-resistant Enterobacterales isolated from clinical samples in Palestine: a focus on extended-spectrum β-lactamase- and carbapenemase-producing isolates. Ibaideya MA; Taha AA; Qadi M BMC Infect Dis; 2024 Aug; 24(1):812. PubMed ID: 39134953 [TBL] [Abstract][Full Text] [Related]
12. Polymyxin resistance in carbapenem-resistant Enterobacteriaceae isolates from patients without polymyxin exposure: a multicentre study in China. Zhang X; Qu F; Jia W; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H Int J Antimicrob Agents; 2021 Feb; 57(2):106262. PubMed ID: 33347990 [TBL] [Abstract][Full Text] [Related]
13. mCIM test as a reliable assay for the detection of CRE in the Gulf region. Al Musawi S; Ur Rahman J; Aljaroodi SA; AlShammari L; Itbaileh A; Mohammed H; Saeed N; Abdalhamid B; Alkharsah KR; Aljindan RY J Med Microbiol; 2021 Jul; 70(7):. PubMed ID: 34232118 [No Abstract] [Full Text] [Related]
14. Carbapenem-heteroresistance among isolates of the Enterobacter cloacae complex: is it a real concern? da Silva AEB; Martins AF; Nodari CS; Magagnin CM; Barth AL Eur J Clin Microbiol Infect Dis; 2018 Jan; 37(1):185-186. PubMed ID: 29170902 [No Abstract] [Full Text] [Related]
15. Clinical and molecular characteristics and risk factors for patients acquiring carbapenemase-producing and non-carbapenemase-producing carbapenem-nonsusceptible-Enterobacterales bacteremia. Wu AY; Chang H; Wang NY; Sun FJ; Liu CP J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1229-1238. PubMed ID: 34824020 [TBL] [Abstract][Full Text] [Related]
16. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. Perovic O; Ismail H; Quan V; Bamford C; Nana T; Chibabhai V; Bhola P; Ramjathan P; Swe Swe-Han K; Wadula J; Whitelaw A; Smith M; Mbelle N; Singh-Moodley A; Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1287-1294. PubMed ID: 32124106 [TBL] [Abstract][Full Text] [Related]
17. Meropenem-Vaborbactam Activity against Carbapenem-Resistant Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207 [TBL] [Abstract][Full Text] [Related]
18. Genomic characterization of an emerging bla Kerdsin A; Deekae S; Chayangsu S; Hatrongjit R; Chopjitt P; Takeuchi D; Akeda Y; Tomono K; Hamada S Sci Rep; 2019 Dec; 9(1):18521. PubMed ID: 31811215 [TBL] [Abstract][Full Text] [Related]
19. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Lee YR; Baker NT Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787 [TBL] [Abstract][Full Text] [Related]
20. Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know. van Duin D Virulence; 2017 May; 8(4):379-382. PubMed ID: 28402724 [No Abstract] [Full Text] [Related] [Next] [New Search]